Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial

C. Mariotti; A. Solari; D. Torta; L. Marano; C. Fiorentini; Stefano Di Donato

Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial

C. Mariotti, A. Solari, D. Torta, L. Marano, C. Fiorentini, Stefano Di Donato

Research output: Contribution to journal › Article › peer-review

Abstract

The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia. They found significant reductions of interventricular septal thickness and left ventricular mass in the idebenone group vs the placebo group, with no improvement in other heart ultrasound measures or neurologic condition. The absolute cardiac changes were modest, but the findings suggest that larger trials should assess whether idebenone reduces ventricular hypertrophy in patients with Friedreich ataxia.

Original language	English
Pages (from-to)	1676-1679
Number of pages	4
Journal	Neurology
Volume	60
Issue number	10
Publication status	Published - May 27 2003

ASJC Scopus subject areas

Neuroscience(all)

Fingerprint Dive into the research topics of 'Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial'. Together they form a unique fingerprint.

Cite this

@article{36c5c6bf82674b5f8db3834961aab35d,

title = "Idebenone treatment in Friedreich patients: One-year-long randomized placebo-controlled trial",

abstract = "The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia. They found significant reductions of interventricular septal thickness and left ventricular mass in the idebenone group vs the placebo group, with no improvement in other heart ultrasound measures or neurologic condition. The absolute cardiac changes were modest, but the findings suggest that larger trials should assess whether idebenone reduces ventricular hypertrophy in patients with Friedreich ataxia.",

author = "C. Mariotti and A. Solari and D. Torta and L. Marano and C. Fiorentini and {Di Donato}, Stefano",

year = "2003",

month = may,

day = "27",

language = "English",

volume = "60",

pages = "1676--1679",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "10",

}

TY - JOUR

T1 - Idebenone treatment in Friedreich patients

T2 - One-year-long randomized placebo-controlled trial

AU - Mariotti, C.

AU - Solari, A.

AU - Torta, D.

AU - Marano, L.

AU - Fiorentini, C.

AU - Di Donato, Stefano

PY - 2003/5/27

Y1 - 2003/5/27

N2 - The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia. They found significant reductions of interventricular septal thickness and left ventricular mass in the idebenone group vs the placebo group, with no improvement in other heart ultrasound measures or neurologic condition. The absolute cardiac changes were modest, but the findings suggest that larger trials should assess whether idebenone reduces ventricular hypertrophy in patients with Friedreich ataxia.

AB - The authors carried out a 1-year, randomized, placebo-controlled trial of idebenone in 29 patients with Friedreich ataxia. They found significant reductions of interventricular septal thickness and left ventricular mass in the idebenone group vs the placebo group, with no improvement in other heart ultrasound measures or neurologic condition. The absolute cardiac changes were modest, but the findings suggest that larger trials should assess whether idebenone reduces ventricular hypertrophy in patients with Friedreich ataxia.

UR - http://www.scopus.com/inward/record.url?scp=0037849955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037849955&partnerID=8YFLogxK

M3 - Article

C2 - 12771264

AN - SCOPUS:0037849955

VL - 60

SP - 1676

EP - 1679

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 10

ER -